The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Unidentified Participant - Cowen and Company - Analyst
: Yes, thank you for taking my questions. You, Paul, with the work you've done on identifying novel mutations I guess what are your latest thoughts
on how many WHIM patients actually exist in the U.S.?
Just -- mostly just reinforced your confidence in the numbers you've put out? Or are you thinking maybe those numbers need to be increased?
Question: Unidentified Participant - Cowen and Company - Analyst
: Okay, that's helpful. And then on the SCN update that we're expecting. Just give a little bit more clarity on the number of patients we should expect?
And then a follow-up that they'll likely have had versus what we saw back in December?
Question: Unidentified Participant - Cowen and Company - Analyst
: Okay, that sounds - and then maybe one for Adam. Just the cash guidance, it seems to me kind of tied to the yearend cash balance, but you did
do a private placement the other day. Is that actually included in the cash guidance? And if not, how does that impact your guidance around there?
And then related to that is can you remind us what the minimum cash covenants are for some of the debt?
Question: Unidentified Participant - Cowen and Company - Analyst
: Okay, great. Bearable, thank you.
Question: Mayank Mamtani - B. Riley Securities - Analyst
: Good morning. Thanks to - for the detailed updates. So a couple of questions from us, just on the core main study, in terms of how you're thinking
about presenting the data top-line and also the full dataset, can - will you have information on the patient level analysis and, if at all, you're targeting
any medical conferences towards the end of the year?
Question: Mayank Mamtani - B. Riley Securities - Analyst
: Yes.
Question: Mayank Mamtani - B. Riley Securities - Analyst
: Okay. And just maybe on that, do you plan to disclose additional base-line characteristics, kind of information, now that you have a lot of information
on these 31 patients that are enrolled? Will there be some more information on those patients or should we just wait until the final top-line?
Question: Mayank Mamtani - B. Riley Securities - Analyst
: Awesome. And [remember], [DNA components], [miss transmutation], the poster you had at the [Quad] conference, just about the implications of
that. Does that help expand [precedence] or also at enterprise maybe more severe patients with that when [there]? Can you [describe by that]?
Question: Mayank Mamtani - B. Riley Securities - Analyst
: Thank you. And then my final question on Waldenstrom, great to see the 600 mg dose [clearing], can you just clarify what your target for deepening
[of responses] look like now that [you're at a] higher dose and exposure is going beyond 12 months for these patients? So just -- could you just
clarify what sort of MR or VGPR numbers you might be targeting?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 17, 2022 / 12:30PM, XFOR.OQ - Q4 2021 X4 Pharmaceuticals Inc Earnings Call
Question: Mayank Mamtani - B. Riley Securities - Analyst
: Thank you for taking my question.
Question: Unidentified Participant - Cowen and Company - Analyst
: Hey, good morning, everyone. This is [Author] in for [RK]. Thanks for taking my question. So I guess I just want to follow up on the patient enrollment
for the Waldenstrom study. So is -- how many patient -- total patient you [have] right now [being through] enrolled in the total study? And how
many patient has been dosed for 600-milligram dose level?
Question: Unidentified Participant - Cowen and Company - Analyst
: Okay, thanks. And maybe a little bit of follow up on that, is the newly enrolled patients are [folks on those are including or] naive [and] refractory
[patient] or is -- [has] more [concreted] in the refractory [patient]?
Question: Unidentified Participant - Cowen and Company - Analyst
: Thank you. Thanks for taking my question.
| 
